THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 64 filers reported holding THESEUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $103,753 | -72.2% | 38,570 | -3.5% | 0.00% | – |
| Q2 2023 | $372,986 | +0.3% | 39,977 | -4.6% | 0.00% | – |
| Q1 2023 | $371,956 | +550.7% | 41,887 | +264.9% | 0.00% | – |
| Q4 2022 | $57,160 | +12.1% | 11,478 | +31.1% | 0.00% | – |
| Q3 2022 | $51,000 | -27.1% | 8,757 | -30.7% | 0.00% | – |
| Q2 2022 | $70,000 | -36.9% | 12,633 | +30.9% | 0.00% | – |
| Q1 2022 | $111,000 | -9.8% | 9,648 | -0.3% | 0.00% | – |
| Q4 2021 | $123,000 | – | 9,679 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,585,346 | $31,837,872 | 23.54% |
| Lynx1 Capital Management LP | 761,258 | $6,759,971 | 5.64% |
| Omega Fund Management, LLC | 711,479 | $6,317,934 | 4.12% |
| Orbimed Advisors | 17,233,668 | $153,034,972 | 3.00% |
| Fairmount Funds Management LLC | 1,865,671 | $16,567,158 | 2.85% |
| Nextech Invest Ltd. | 611,310 | $5,428,433 | 2.27% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $19,963,963 | 1.44% |
| VR Adviser, LLC | 770,000 | $6,837,600 | 1.34% |
| Opaleye Management Inc. | 488,100 | $4,334,328 | 1.30% |
| Paradigm Biocapital Advisors LP | 1,505,327 | $13,367,304 | 1.27% |